FGP
RPRX icon

Freestone Grove Partners’s Royalty Pharma RPRX Stock Holding History

Freestone Grove Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
4,670
-611,707
-99% -$31.8M ﹤0.01% 778
2026
Q1 		$29.6M Buy
+616,377
New +$27M 0.21% 162

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's RPRX Position: Q2 2026 in Review

Freestone Grove Partners reduced its Royalty Pharma (RPRX) stake by 99% in Q2 2026, selling an estimated $31.8M and leaving 4,670 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #778.

Freestone Grove Partners first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $29.6M in Q1 2026. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Freestone Grove Partners held 4,670 shares of Royalty Pharma worth $262K as of Q2 2026.
  • Freestone Grove Partners sold 611,707 Royalty Pharma shares in Q2 2026, an estimated $31.8M.
  • Royalty Pharma made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #778 holding.
  • Freestone Grove Partners first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • Freestone Grove Partners's Royalty Pharma position peaked at $29.6M in Q1 2026.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.